Therapeutic Guidelines in Systemic Fungal Infection 3rd ed.

[sarlo518]

Therapeutic Guidelines in Systemic Fungal Infection 3rd ed.
By Malcolm D Richardson, Brian L. Jones, Riina Rautemaa

​

• Publisher: --
• Pages: 126
• Edition: 3rd., 2007
• ISBN-10 / ASIN: 1905721056
• ISBN-13 / EAN: 9781905721054

Description

Contents Preface to the First Edition vii Preface to the Third Edition viii Clinical and Laboratory Diagnosis 1 1 Definitions of fungal infections 2 2 Categories of risk groups for systemic fungal infection 7 3 Essential clinical examination in neutropenic and solid organ transplant patients with suspected invasive fungal infection 8 4 Investigation of pulmonary infection in neutropenic and solid organ transplant patients 9 5 Essential investigations for the laboratory diagnosis of systemic fungal infections 10 6 Fungal species most commonly recovered from clinical specimens 17 7 Criteria for the diagnosis of systemic fungal infections: clinical features and laboratory parameters contributing to a definitive diagnosis 19 8 Assessment of the response to antifungal therapy – definitions 22 iv Antifungal Drugs 23 9 Amphotericin B 24 10 Regimen for rapid escalation of amphotericin B dosage 27 11 Regimen for gradual escalation of amphotericin B dosage 28 12 Liposomal amphotericin B (AmBisome®) 29 13 Amphotericin B colloidal dispersion (Amphocil®, Amphotec®) 33 14 Amphotericin B lipid complex (Abelcet®) 37 15 Pharmacokinetic comparisons of amphotericin B formulations 40 16 Polyene comparisons: infusion-related reactions 41 17 Polyene comparisons: nephrotoxicity 43 18 Caspofungin 44 19 Fluconazole 48 20 Flucytosine (5-fluorocytosine) 53 21 Regimens for administration of flucytosine in renal impairment 56 v 22 Itraconazole 57 23 Voriconazole 64 Therapy of Specific Infections 69 24 Aspergillosis 70 25 Prevention of invasive aspergillosis 75 26 Blastomycosis 78 27 Candidosis 80 28 Coccidioidomycosis 86 29 Cryptococcosis 88 30 Histoplasmosis 91 31 Mucormycosis 94 32 Paracoccidioidomycosis 96 33 Penicillium marneffei infection 97 34 Sporotrichosis 98 vi 35 Unusual fungal infections 99 Prophylaxis 101 36 Prophylaxis alternatives 102 37 Examples of risk factors triggering targeted prophylaxis/pre-emptive therapy 105 Empirical Treatment of the Persistently Febrile Neutropenic Patient 106 38 Recommended empirical treatment 107 39 Current recommended initial strategy 108 Combination Treatment and Antifungals Under Development 109 40 Combination therapy: the issues 110 41 Antifungals under development 111 General references 115 Web sites 117 Abbreviations 118


​

 

[Micotil]

2007

To view the content, you need to Sign In or Register.